A Randomized, Double-Blind, Double-Dummy, Multicenter, Active-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab IV Compared to Adalimumab SC in Subjects With Ulcerative Colitis - Efficacy and Safety of Vedolizumab IV Compared to Adalimumab SC in Subjects With Ulcerative Colitis

Takeda Development Centre Europe, Ltd.0 个研究点目标入组 771 人开始时间: 2015年10月29日最近更新: 2020年7月20日

试验速览

暂无简介。

•1.Has a diagnosis of ulcerative colitis established at least 3 months prior to screening by clinical and endoscopic evidence and corroborated by a histopathology report.
•2.Has moderately to severely active ulcerative colitis as determined by a Mayo score of 6 to 12 with an endoscopic subscore greater than or equal to >=2 within 14 days prior to the randomization.
•3.Has evidence of ulcerative colitis proximal to the rectum (>=15 centimeter [cm] of involved colon).
•4.a.Has had previous treatment with tumor necrosis factor–alpha (TNF-a) antagonists without documented clinical response to treatment (eg, due to lack of response [primary nonresponders], loss of response, or intolerance [secondary nonresponder], or b. Has previously used a TNF-a antagonist (except adalimumab), and discontinued its use due to reasons other than safety.
•5. Is naïve to TNF-a antagonist therapy but is failing current treatment (ie, corticosteroids, 5-aminosalicylate, or immunomodulators).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 735
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 23

•1.The subject has had an extensive colonic resection, subtotal or total colectomy.
•2.The subject has any evidence of an active infection during Screening.
•3.The subject has a positive progressive multifocal leukoencephalopathy (PML) subjective symptom checklist at Screening or before the administration of study drug at Day 1.
•4. The subject has received any investigational or approved biologic or biosimilar agent (other than those listed below) within 60 days or 5 half lives prior to screening (whichever is longer).
•5. The subject has had prior exposure to vedolizumab, natalizumab, efalizumab, adalimumab, etrolizumab, AMG-181, anti–mucosal addressin cell adhesion molecule-1 (MAdCAM-1)-antibodies, or rituximab.

发起方